Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Nov;16(8):697-705.
doi: 10.1177/1087054711425772. Epub 2011 Nov 14.

Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD

Affiliations
Randomized Controlled Trial

Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD

Robert B Armstrong et al. J Atten Disord. .

Abstract

Objective: The authors evaluated the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS(®) MPH) HCl (Concerta(®), Raritan, NJ) CII in children with ADHD.

Method: Data were combined from two double-blind, randomized, placebo-controlled, cross-over, analog classroom studies in children (9-12 years) with ADHD. Participants received an individualized dose of placebo or OROS(®) MPH on two laboratory school days. Permanent Product Math Test and Swanson, Kotkin, Agler, M-Flynn, and Pelham scores were evaluated 0.5 hr before dosing and 1, 2, 4, 10, 11, and 12.5 hr post dose. Analysis used a repeated-measures mixed model.

Results: Treatment effects were present at all postdose assessment points (p < .0001 for all comparisons, n = 139). Adverse events were similar to previous reports for OROS(®) MPH.

Conclusion: A robust treatment effect occurred with OROS(®) MPH; onset was at 1 hr and persisted for at least 12.5 hr after dosing.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

Publication types

Substances

LinkOut - more resources

Feedback